KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by Silverarc Capital Management LLC

Silverarc Capital Management LLC boosted its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 6.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 612,173 shares of the specialty pharmaceutical company's stock after purchasing an additional 37,615 shares during the period. Silverarc Capital Management LLC owned approximately 1.24% of KalVista Pharmaceuticals worth $5,185,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. SG Americas Securities LLC boosted its position in shares of KalVista Pharmaceuticals by 10.0% in the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after buying an additional 1,319 shares during the period. Legal & General Group Plc boosted its holdings in KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after acquiring an additional 1,494 shares during the period. JPMorgan Chase & Co. boosted its holdings in KalVista Pharmaceuticals by 8.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company's stock worth $262,000 after acquiring an additional 1,670 shares during the period. China Universal Asset Management Co. Ltd. grew its position in KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after acquiring an additional 2,043 shares in the last quarter. Finally, AlphaQuest LLC raised its stake in shares of KalVista Pharmaceuticals by 17.1% during the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock valued at $150,000 after purchasing an additional 2,588 shares during the period.

Insiders Place Their Bets

In related news, insider Paul K. Audhya sold 3,125 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $30,687.50. Following the sale, the insider now owns 100,334 shares in the company, valued at $985,279.88. This represents a 3.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Benjamin L. Palleiko sold 6,669 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $11.97, for a total value of $79,827.93. Following the completion of the transaction, the chief executive officer now owns 287,811 shares of the company's stock, valued at approximately $3,445,097.67. The trade was a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have bought 261,055 shares of company stock valued at $2,397,646 and have sold 17,292 shares valued at $184,625. 10.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on KALV shares. JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They set an "outperform" rating and a $19.00 price target for the company. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Jones Trading reissued a "buy" rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Finally, TD Cowen initiated coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating and a $30.00 price objective for the company. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $24.83.

KalVista Pharmaceuticals Price Performance

NASDAQ:KALV traded up $0.11 during mid-day trading on Friday, reaching $12.99. The stock had a trading volume of 347,939 shares, compared to its average volume of 405,585. The company has a market capitalization of $645.81 million, a price-to-earnings ratio of -3.57 and a beta of 0.39. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50. The stock's 50 day simple moving average is $11.61 and its two-hundred day simple moving average is $10.36.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).